Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance
Year: 2021
Type: article
Abstract: are the fosfomycin and amikacin MICs, respectively). Monte Carlo simulations predict that a standard fosfomycin-amikacin neonatal regimen would achieve >99% probability of pharmacodynamic success for strains with MICs below this threshold. We conclude that the combination of fosfomycin with amikacin is a viable regimen for the empirical treatment of neonatal sepsis and is suitable for further clinical assessment in a randomized controlled trial.
DOI: 10.1128/aac.00293-21
Authors: Christopher A. Darlow, Fernando Docobo-Perez, Nicola Farrington, Adam Johnson, Laura McEntee, Jennifer Unsworth, Ana Jimenez-Valverde, Silke Gastine, Ruwanthi Kolamunnage-Dona, Renata M. A. de Costa, Sally Ellis, François Franceschi, Joseph F. Standing, Mike Sharland, Michael Neely, Laura Piddock, Shampa Das, William Hope
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Eli Lilly and Company, UK Research and Innovation, National Institute for Health and Care Research, University of Oxford, University of Manchester, University of Liverpool, Bundesministerium für Bildung und Forschung, Department for International Development, Bundesministerium für Gesundheit, Medical Research Council, UCB Pharma
OpenAlex ID: W3159338233